ARID1A and cancer: Similarly, across 7 studies [14, 18, 19, 22, 27, 28, 35], recurrence of cancer did not differ between the two groups, with 98/454 (21.6%) recurrences in those with ARID1A− vs. 76/373 (20.4%) in those with ARID1A+ (RR = 1.11, 95%CI: 0.98–1.25, p = 0.10, I2 = 51%) (Table 1; Supplementary Figure 3).